Fennec Pharmaceuticals (FENC) Free Cash Flow (2010 - 2025)
Fennec Pharmaceuticals' (FENC) quarterly Free Cash Flow came in at -$6.0 million in Q4 2025, down 304.48% YoY from $2.9 million in Q4 2024, and down 499.33% on a QoQ basis from $1.5 million in Q3 2025.
Fennec Pharmaceuticals (FENC) Free Cash Flow (2010 - 2025) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 16 years of Free Cash Flow data on file, last reported at -$6.0 million in Q4 2025.
- Quarterly Free Cash Flow fell 304.48% year-over-year to -$6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12.5 million (down 149.42% YoY) and the FY2025 annual result came in at -$15.3 million, down 156.58% from the prior year.
- Free Cash Flow slipped to -$6.0 million in Q4 2025, from $1.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $37.3 million in Q1 2024 to a low of -$8.4 million in Q2 2024.
- A 5-year average of -$1.8 million and a median of -$3.6 million in 2021 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow surged 768.94% — and 2025, when it tumbled 304.48%.
- Tracing FENC's Free Cash Flow over 5 years: stood at -$3.2 million in 2021, then sank by 109.61% to -$6.8 million in 2022, then rose by 28.55% to -$4.9 million in 2023, then surged by 69.67% to -$1.5 million in 2024, then plunged by 304.48% to -$6.0 million in 2025.
- The last three Free Cash Flow figures came in at -$6.0 million (Q4 2025), $1.5 million (Q3 2025), and -$3.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Fennec Pharmaceuticals | 410.60 Mn | 369.35 Mn | 17.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.96 Mn |
| Dec 31, 2025 | -5.96 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Jun 30, 2025 | -3.69 Mn |
| Jun 30, 2025 | -3.69 Mn |
| Mar 31, 2025 | -4.32 Mn |
| Mar 31, 2025 | -4.32 Mn |
| Dec 31, 2024 | -1.47 Mn |
| Dec 31, 2024 | -1.47 Mn |
| Sep 30, 2024 | -2.21 Mn |
| Sep 30, 2024 | -2.21 Mn |
| Jun 30, 2024 | -8.39 Mn |
| Jun 30, 2024 | -8.39 Mn |
| Mar 31, 2024 | 37.31 Mn |
| Mar 31, 2024 | 37.31 Mn |
| Dec 31, 2023 | -4.86 Mn |
| Dec 31, 2023 | -4.86 Mn |
| Sep 30, 2023 | -2.76 Mn |
| Sep 30, 2023 | -2.76 Mn |